HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study

July 10, 2008

In battle with an epidemic that has outpaced nearly all efforts to contain it, researchers are turning to strategies centered on the same antiretroviral (ARV) drugs that have been used successfully to treat HIV in hopes they will be as effective a stronghold for preventing the virus. For women, who make up nearly half of the 33 million people living with HIV/AIDS worldwide, the ARV tenofovir has particular promise because it can be formulated as either an oral tablet or a vaginal gel to be used daily. But ARV-based prevention approaches are not without scientific and practical challenges. The Microbicide Trials Network (MTN) is taking aim at among the most pressing of these challenges in the first clinical trial to directly compare the tablet and vaginal gel formulations of tenofovir.

In part because certain cells in the vagina are easy targets for the virus, women are more than twice as likely as their male partners to acquire HIV through sexual intercourse. As such, the clinical study, known as MTN-001, seeks to understand how each formulation of tenofovir works in these infection-prone cells, information that will help researchers determine the optimal doses needed to achieve drug concentrations most likely to prevent HIV in women.

MTN-001 also looks to understand the factors that influence women's preferences for one daily approach over another, because not even the best approach will be effective if women don't use it.

MTN-001 is a Phase II study designed to evaluate women's adherence to and acceptance of three daily regimens of tenofovir - tenofovir gel, tenofovir disoproxil fumarate tablets and the two together - and the pharmacokinetics, or how the drug is absorbed by and distributed in the body over time, of each regimen. The study will enroll 144 sexually active HIV-negative women who will follow all three regimens, each for six weeks with one week between when no study product is used. In the United States, Case Western Reserve University in Cleveland and the University of Pittsburgh are now beginning to screen potential participants.

Additional sites, including in South Africa and Uganda, will also be participating in the study, which is funded by the National Institute of Allergy and Infectious Diseases, a component of the U.S. National Institutes of Health. Researchers expect to complete the study in 2009.

"Being able to capture in one study, and in all women, information about adherence, acceptability, and pharmacokinetics will help us answer critical questions about the three regimens more efficiently and with greater confidence than we could in separate studies. We will be able to more clearly discern the differences between each formulation, including at the cellular level, and get a more accurate reading on women's preferences and adherence patterns," said Craig W. Hendrix, M.D., associate professor of medicine, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine in Baltimore, Maryland, who, as MTN-001 protocol chair, is leading the multi-site study.

In its tablet form, tenofovir disoproxil fumarate, known by the brand name Viread, is a mainstay of one of the most widely used regimens for treating HIV. The active ingredient in tenofovir belongs to a class of ARVs called nucleotide reverse transcriptase inhibitors (NRTIs), which act against HIV by targeting a key enzyme the virus needs to make a copy of its genetic material - an essential step for the virus to multiply and infect other cells. Tenofovir is being evaluated in clinical trials to determine if this first-line treatment can also prevent HIV when used every day by people who are HIV-negative, an approach known as pre-exposure prophylaxis, or PrEP. As a vaginal gel, tenofovir is among a newer class of candidate microbicides with specific activity against HIV. Microbicides are substances designed to prevent or reduce the sexual transmission of HIV when applied topically on the inside of the vagina or rectum.

In MTN-001, researchers will assess women's adherence to each of the three tenofovir regimens through structured interviews and questionnaires. Questions will focus on their overall experience using the product regimen, asking how sexual activity may have changed, how well the regimen was adhered to and why the product was not always used- did they forget, dislike using the product or give the tablet or gel to other people? A small number of participants from each site also will take part in in-depth interviews at the end of the 21-week study so researchers can collect more detailed information, including about women's adherence to and preferences between oral and vaginal formulations and between single and dual-use regimens.

Researchers will conduct pharmacokinetic studies of blood plasma (the liquid component of blood), white blood cells, vaginal tissue and cells taken from inside the vagina. For instance, at each mid-study period, participants will provide a small amount of blood that will be used to determine how much tenofovir is circulating in the blood. At sites with laboratory capacity, blood will also be used to determine if tenofovir is present inside blood cells and, if so, whether the drug is in its active or inactive state. Such studies are important because tenofovir is not effective against HIV unless it has been activated by the addition of two molecules called phosphates, much like a lamp can only be turned on if it has both a light bulb and switch.

At the end of each study period, participants will follow their assigned regimen at the clinic, and similar tests will be conducted of both blood and vaginal fluid. The 48 women enrolled at the two U.S. sites will be involved in more intensive assessments of each approach whereby researchers will look at blood and tissue samples at different periods of time after taking the drug.

"Information gathered in these intensive studies, plus information from other trials, will help us build a picture showing the relationship between plasma blood levels of drug and the amount of activated drug inside the HIV target cells of vaginal tissue. It may be possible to determine the concentration of drug inside vaginal cells with a simple blood test, and then extrapolate the required drug dose to reach the target concentration for preventing HIV," explained Dr. Hendrix.

MTN-001 is part of a portfolio of trials evaluating the oral and gel forms of tenofovir. Recently, MTN researchers launched the first trial in pregnant women, seeking to understand the extent that pregnancy affects how the body absorbs the active drug in the gel and whether the drug can be transferred to the fetus. The VOICE Study (Vaginal and Oral Interventions to Control the Epidemic), a trial involving 4,300 women that is expected to begin early 2009, will be the first effectiveness trial evaluating in the same study both a microbicide (tenofovir gel) and PrEP (oral tenofovir and oral Truvada, a combination of tenofovir disoproxil fumarate and another antiretroviral agent called emtricitabine).

Microbicide Trials Network

---

---

	Basic and Clinical Pharmacology 12/E (LANGE Basic Science) by Bertram Katzung (Author), Susan Masters (Author), Anthony Trevor (Author) The most up-to-date, comprehensive, and authoritative pharmacology text in health medicine Enhanced by more than three hundred illustrations -- many in full color Organized to reflect the syllabi in many pharmacology courses and in integrated curricula, Basic & Clinical Pharmacology, 12e covers the important concepts students need to know about the science of pharmacology and its application to clinical practice. Selection of the subject matter and order of its presentation are based on the authors’ many years experience in teaching this material to thousands of medical, pharmacy, dental, podiatry, nursing, and other health science students. To be as clinically relevant as possible, the book includes sections that specifically address the clinical choice and use of drugs in patients...
	The APhA Complete Review for Pharmacy (Gourley, APha Complete Review for Pharmacy) by Dick R. Gourley (Author), James C. Eoff (Author), III (Author) The NAPLEX (North American Pharmacist Licensure Examination) is the standard licensing exam that all U.S. pharmacy students must pass to practice pharmacy. It's an arduous exam that tests a daunting range of knowledge. Approximately 10 per cent of students taking the exam for the first time fail to achieve a passing score. Preparing for the NAPLEX by reviewing all of the material from each pharmacy school course would be overwhelming. A far better approach would be to study only the information most relevant to the exam, summarized in abbreviated bullet format - and that's what The APhA Complete Review for Pharmacy contains. Features of this title include: Top 200 drugs: Begin your NAPLEX preparation by learning the generic and trade names for the top 200 drugs, Math: After...
	Pharmacology for the Primary Care Provider, 3e (Edmunds, Pharmacology for the Primary Care Provider) by Marilyn Winterton Edmunds PhD ANP/GNP (Author), Maren Stewart Mayhew MS ANP (Author) Written by and for nurse practitioners, this practical textbook focuses on what primary care providers need to learn and practice drug therapy. With an overall emphasis on patient teaching and health promotion, you will learn how to provide effective patient teaching about medications and how to gain patient compliance. Drug coverage focuses on "key drugs” rather than "prototype drugs,” so you can find important information about the most commonly used drugs rather than the first drug in each class. You will also find discussions on the legal and professional issues unique to nurse practitioners and other primary care providers. The 3rd edition also features an expanded emphasis on established clinical practice guidelines and evidence-based practice, plus two new chapters that cover...
	Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition by Laurence Brunton (Author), Bruce Chabner (Author), Bjorn Knollman (Author) The landmark text in medical pharmacology is now in full color Includes DVD with image bank A Doody's Core Title ESSENTIAL PURCHASE for 2011! 4 STAR DOODY'S REVIEW! "This 12th edition of the most authoritative book in pharmacology is the best both in content and physical appearance....This edition of Goodman & Gilman's continues to be the most authoritative and widely used resource bridging the discipline of pharmacology with therapeutics. Moreover, readers will find this edition to be substantially improved from past editions in both content and physical appearance."--Doody's Review Service The most universally respected and read medical text in all of pharmacology, Goodman & Gilman’s The Pharmacological Basis of Therapeutics represents the pinnacle of authority and accuracy in...
	Nursing2010 Drug Handbook with Web Toolkit (Nursing Drug Handbook (Lww)) by Lippincott (Author) The best-selling nursing drug handbook for 30 years is now in its fully updated 2010 edition. Organized by therapeutic class, Nursing2010 Drug Handbook provides quick access to current, accurate information on over 900 generic and 3,000 brand-name drugs. This edition includes black box warnings where appropriate, an expanded combination drug section, vaccine immunization schedules, and more than 1,350 additions, changes, and updates on indications, dosages, and administration.The monographs are consistently formatted for ease of use, and they focus on the practical information that practicing nurses need. Each monograph consists of generic and trade names, pronunciation key, pregnancy risk category, pharmacologic class, controlled substance schedule (if applicable), available forms,...
	Nursing 2011 Drug Handbook with Online Toolkit (Nursing Drug Handbook) by Lippincott (Author) The Best-Selling Nursing Drug Reference - More Than 5 Million Sold! The Nursing 2011 Drug Handbook with Online Toolkit, the newest edition of the drug guide trusted by practicing nurses and nursing students for over 30 years, is what you need to keep your patients safe and your drug knowledge current. Comprehensive coverage of over 3,300 generic and trade name drugs - including new monographs for 39 new FDA-approved drugs - put the drug information you need at your fingertips. Organized by therapeutic class AND alphabetical index, with over 1,300 drug information updates, this handbook helps you prevent drug errors and administer medications safely and accurately. Putting the focus on patient safety Patient safety is your number one priority, and...
	PDR Pocket Guide to Prescription Drugs, 9th Edition by Thompson PDR (Author) Everything you need to know about prescription drugs -- based on the FDA-approved information published in the Physicians' Desk Reference® Why was this drug prescribed for me? What are the benefits and risks of taking this drug? Are there any side effects I should watch for? What questions should I ask my doctor about this prescription? You'll find the answers to all these questions and more in this accessible, up-to-date resource. The drug profiles in this consumer handbook are based on the Physicians' Desk Reference® -- the trusted guide to safe, effective drug therapy that health-care professionals have used for more than 60 years. FEATURES COMPLETELY UPDATED FORMAT THAT MATCHES THE FDA 'S NEWEST...
	Nursing2012 Drug Handbook with Online Toolkit (Nursing Drug Handbook) by Lippincott (Author) The 32nd edition of the best-selling, original drug handbook for nurses has been revised, updated, and completely redesigned—with generic drugs alphabetically arranged for even faster access to drug and patient care information!  This reliable guide offers comprehensive information on more than 1,000 generic and 3,000 brand-name drugs, with special attention given to maintaining patient safety: readers will find tall-man lettering, prominent black box warnings and clinical alerts, overdose signs and symptoms,  look alike-sound alike drugs, easy-to-spot drug action and I.V. administration information, a new chapter on safe drug administration, and three brand-new appendices covering best practices for avoiding common drug errors, pediatric drugs commonly...
	Johns Hopkins HIV Guide 2012 by Joel E. Gallant (Author) Based On The Same Award-Winning Content As The Johns Hopkins POC-IT Center Online Database, The Johns Hopkins HIV Guide 2012 Is The Most Up-To-Date HIV Treatment And Management Resource On The Market. Written By Dr. Joel E. Gallant, World Renowned Expert In The Field Of HIV And Infectious Disease, This Concise And Well-Organized Medical Reference Is Broken Down Into Several Modules, Including: Diagnosis And Evaluation, Treatment Options, Resistance And Complications, Prophylaxis And Antiretroviral Drug Summaries. Johns Hopkins HIV Guide 2012 Contains The Most Current, Relevant And Evidence-Based Information On HIV And AIDS. Selected Topics Include: • Antiretroviral Therapy Adverse Effects • HIV Antibody Testing • Important Genotype-Resistant Patterns • Musculoskeletal And...
	Comprehensive Pharmacy Review by Leon Shargel (Author), Alan H. Mutnick (Author), Paul F. Souney (Author), Larry N. Swanson (Author) Completely revised to reflect current progress in pharmacy education and practice, the Seventh Edition of this best-selling review guide is indispensable for all pharmacy students, from the first year of professional courses to preparation for the NAPLEX® examination. A wide range of topics central to the study of pharmacy—chemistry, pharmaceutics, pharmacology, pharmacy practice, drug therapy—are organized to parallel the pharmacy curriculum and presented in outline form for easy use. Comprehensive Pharmacy Review may be used as a quick review or preview of essential topics by a diverse group of readers, including matriculation pharmacy students, instructors and preceptors, professional pharmacists, and foreign pharmacy graduates.